Cargando…

Comparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial Study

OBJECTIVE: To compare the incidence rate of carboplatin hypersensitivity reactions (HSRs) in gynecologic cancer patients receiving one-hour or two-hour carboplatin retreatment infusions. SETTING: A Prospective Randomized Controlled Trial. METHODS: Recurrent gynecologic cancer patients 25 to 80-years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pornwattanakrilert, Weerawich, Suprasert, Prapaporn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454738/ https://www.ncbi.nlm.nih.gov/pubmed/28345825 http://dx.doi.org/10.22034/APJCP.2017.18.2.425

Ejemplares similares

Carboplatin-Induced Hypersensitivity Reaction
por: Potolidis, Evangelos, et al.
Publicado: (2012)

Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
por: Tai, Yu-Hsiao, et al.
Publicado: (2017)

Micturition symptoms in gynecologic cancer patients receiving paclitaxel and platinum-based chemotherapy regimen: a prospective study
por: Wudtisan, Jongpeeti, et al.
Publicado: (2023)

Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy
por: Williams, Laura, et al.
Publicado: (2009)

Prevalence of malnourishment and predictive factors associated with the nutritional status of gynecologic cancer patients undergoing chemotherapy: a cross-sectional analysis
por: Sanguanwongthong, Khemmanat, et al.
Publicado: (2022)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Prevalence and risk factor of post-operative lower extremities deep vein thrombosis in patients undergoing gynecologic surgery: a single-institute cross-sectional study
por: Lorchaivej, Supakorn, et al.
Publicado: (2022)

Hypersensitivity to Carboplatin in Children with Malignancy
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

Cancer Antigen 125 during Pregnancy in Women without Ovarian Tumor Is Not Often Rising
por: Amampai, Rattapon, et al.
Publicado: (2018)

Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy
por: Jeerakornpassawat, Dhammapoj, et al.
Publicado: (2020)

Oncology and reproductive outcomes over 16 years of malignant ovarian germ cell tumors treated by fertility sparing surgery
por: Rungoutok, Muangloei, et al.
Publicado: (2022)

Anaphylactic reaction to carboplatin diagnosed by skin testing—a reliable tool in platinum-based immediate-type hypersensitivity reactions
por: Marquart, Elias, et al.
Publicado: (2022)

Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study
por: Oude Elberink, Hanneke N. G., et al.
Publicado: (2020)

Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
por: Pandey, Avinash, et al.
Publicado: (2014)

Treatment Outcomes of Patients with Squamous Cell Carcinoma of the Vulva: The Largest Series from a Tertiary Care Hospital
por: Meelapkij, Panida, et al.
Publicado: (2018)

Clinicopathological Prognostic Factors Influencing Survival Outcomes of Vulvar Cancer
por: Muangchang, Monwanee, et al.
Publicado: (2021)

Carboplatin-induced severe hypersensitivity reaction: Role of IgE-dependent basophil activation and FcεRI
por: Iwamoto, Takuya, et al.
Publicado: (2014)

Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion
por: Nath, Proggananda, et al.
Publicado: (2014)

Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
por: Berger, Michael J., et al.
Publicado: (2011)

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
por: Maurer, Kathryn, et al.
Publicado: (2017)

Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients
por: Chantzichristos, Dimitrios, et al.
Publicado: (2008)

Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma
por: Rewsuwan, Sunida, et al.
Publicado: (2016)

Primary signet ring cell carcinoma with neuroendocrine differentiation arising in mucinous borderline tumor of the ovary
por: Pongsuvareeyakul, Tip, et al.
Publicado: (2019)

Profiling the Expression and Prognostic Values of FYN, A Non-Receptor Tyrosine Kinase, in Different Histological Types of Epithelial Ovarian Cancer
por: Dankai, Wiyada, et al.
Publicado: (2023)

Does Carboplatin Rapid Desensitization Change Its Adverse Drug Reactions Other than Hypersensitivity and Efficacy in Patients With Ovarian Cancer?
por: Park, Han-Ki, et al.
Publicado: (2020)

Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity
por: Laskey, Robin A, et al.
Publicado: (2014)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Efficacy of Listening to Music on Pain Reduction during Colposcopy-Directed Cervical Biopsy: A Randomized, Controlled Trial
por: Pradit, Lalita, et al.
Publicado: (2022)

Tuberculosis retreatment ‘others’ in comparison with classical retreatment cases; a retrospective cohort review
por: Nabukenya-Mudiope, Mary G., et al.
Publicado: (2015)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

Poorly Differentiated Thyroid Carcinoma Arising in Struma Ovarii
por: Khunamornpong, Surapan, et al.
Publicado: (2015)

Clear-Cell Mesothelioma of Uterine Corpus: Diagnostic Challenges in Intraoperative Frozen Sections
por: Pongsuvareeyakul, Tip, et al.
Publicado: (2023)

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations
por: Garcia, Andrew, et al.
Publicado: (2019)

Effectiveness of premedication for hypersensitivity reactions to radiocontrast media in one tertiary hospital
por: Jung, JaeWoo, et al.
Publicado: (2014)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Itolizumab/sodium chloride: Second degree heart block secondary to infusion related hypersensitivity reaction: case report
Publicado: (2021)

Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study
por: Holmes, Jarrod P., et al.
Publicado: (2021)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
por: Watanabe, Yuko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pvjulkbkvit1eagqj39d77n4lc